Limb-salvage reconstruction with MUTARS hemipelvic endoprosthesis: a prospective multicenter study

Area of Science:

• Orthopedic oncology
• Surgical reconstruction
• Prosthetic implants

Background:

• Limb-sparing surgery using hemipelvic megaprosthetic replacement is associated with significant complication rates.
• Evaluating clinical and oncological outcomes is crucial for understanding the impact of post-operative complications.

Purpose of the Study:

• To assess the clinical and oncological findings related to hemipelvic megaprosthetic replacement.
• To evaluate the type, treatment, and outcomes of post-operative complications.

Main Methods:

• A prospective multicenter study evaluated 40 patients treated with custom MUTARS hemipelvic endoprostheses.
• Follow-up data was collected and analyzed for clinical and oncological outcomes.

Main Results:

• The mean follow-up was 24 months. Overall survival rates at one and two years were 89% and 81%, respectively.
• Complications occurred in 75% of patients, mainly wound-related. Implant revision was needed in 22.5% of cases.
• The estimated three-year implant survival rate was 61.4%.

Conclusions:

• Periacetabular endoprosthetic replacement provides acceptable functional and oncological results.
• A high complication rate, particularly infections, was observed.
• The use of hemipelvic prostheses in metastatic disease warrants serious consideration.